Phibro Animal Health Corporation $PAHC Shares Sold by Wakefield Asset Management LLLP

Wakefield Asset Management LLLP cut its holdings in shares of Phibro Animal Health Corporation (NASDAQ:PAHC) by 24.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 39,328 shares of the company’s stock after selling 12,842 shares during the quarter. Wakefield Asset Management LLLP’s holdings in Phibro Animal Health were worth $1,591,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Geode Capital Management LLC raised its holdings in Phibro Animal Health by 1.4% in the 2nd quarter. Geode Capital Management LLC now owns 554,927 shares of the company’s stock valued at $14,175,000 after buying an additional 7,841 shares during the period. Millennium Management LLC increased its position in shares of Phibro Animal Health by 74.3% during the first quarter. Millennium Management LLC now owns 362,030 shares of the company’s stock valued at $7,733,000 after acquiring an additional 154,281 shares during the last quarter. Ranger Investment Management L.P. increased its position in shares of Phibro Animal Health by 101.1% during the second quarter. Ranger Investment Management L.P. now owns 357,970 shares of the company’s stock valued at $9,143,000 after acquiring an additional 179,975 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its stake in shares of Phibro Animal Health by 43.2% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 275,066 shares of the company’s stock valued at $7,025,000 after acquiring an additional 83,018 shares during the period. Finally, Barclays PLC lifted its holdings in shares of Phibro Animal Health by 47.4% in the 3rd quarter. Barclays PLC now owns 269,568 shares of the company’s stock worth $10,907,000 after acquiring an additional 86,719 shares during the last quarter. 99.34% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently weighed in on PAHC. Morgan Stanley set a $49.00 price objective on shares of Phibro Animal Health in a research report on Friday, February 6th. Zacks Research cut Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research note on Monday, February 9th. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of Phibro Animal Health in a research report on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $37.50.

Phibro Animal Health Price Performance

PAHC stock opened at $50.43 on Wednesday. The business’s 50-day moving average is $45.59 and its two-hundred day moving average is $41.95. The company has a debt-to-equity ratio of 2.14, a current ratio of 3.05 and a quick ratio of 1.22. The firm has a market capitalization of $2.04 billion, a P/E ratio of 22.41, a P/E/G ratio of 0.75 and a beta of 0.74. Phibro Animal Health Corporation has a 1 year low of $16.16 and a 1 year high of $56.30.

Phibro Animal Health (NASDAQ:PAHC) last released its earnings results on Wednesday, February 4th. The company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.69 by $0.18. Phibro Animal Health had a net margin of 6.29% and a return on equity of 38.28%. The firm had revenue of $373.91 million for the quarter, compared to analyst estimates of $355.64 million. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. Analysts anticipate that Phibro Animal Health Corporation will post 1.95 earnings per share for the current fiscal year.

Phibro Animal Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Wednesday, March 4th will be paid a dividend of $0.12 per share. The ex-dividend date is Wednesday, March 4th. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.0%. Phibro Animal Health’s payout ratio is presently 21.33%.

Insiders Place Their Bets

In other Phibro Animal Health news, CEO Jack Bendheim sold 7,040 shares of Phibro Animal Health stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $53.73, for a total transaction of $378,259.20. Following the completion of the sale, the chief executive officer directly owned 1,480 shares of the company’s stock, valued at $79,520.40. The trade was a 82.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders sold 294,392 shares of company stock valued at $14,056,947 in the last 90 days. 50.13% of the stock is owned by company insiders.

Phibro Animal Health Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.